NYSE:BMYPharmaceuticals
What Bristol-Myers Squibb (BMY)'s Earnings Rebound and Completed Buybacks Mean For Shareholders
In early February 2026, Bristol-Myers Squibb reported fourth-quarter 2025 revenue of US$12,502 million and net income of US$1,087 million, while confirming completion of a long-running share repurchase program totaling 475,816,819 shares for US$29,984.88 million since its announcement in October 2016.
The sharp swing from a full-year 2024 net loss to a 2025 net profit of US$7.05 billion highlights how earnings have recovered even as annual revenue stayed broadly flat at about US$48.19...